Pterostilbene-Isothiocyanate Conjugate Suppresses Growth of Prostate Cancer Cells Irrespective of Androgen Receptor Status

Abstract

Chemotherapy and anti-hormonal therapies are the most common treatments for non-organ-confined prostate cancer (PCa). However, the effectiveness of these therapies is limited, thus necessitating the development of alternative approaches. The present study focused on analyzing the role of pterostilbene (PTER)-isothiocyanate (ITC) conjugate – a novel class of hybrid compound synthesized by appending an ITC moiety on PTER backbone – in regulating the functions of androgen receptor (AR), thereby causing apoptosis of PCa cells. The conjugate molecule caused 50% growth inhibition (IC50) at 40±1.12 and 45±1.50 μM in AR positive (LNCaP) and negative (PC-3) cells, respectively. The reduced proliferation of PC-3 as well as LNCaP cells by conjugate correlated with accumulation of cells in G2/M phase and induction of caspase dependent apoptosis. Both PI3K/Akt and MAPK/ERK pathways played an important and differential role in conjugate-induced apoptosis of these PCa cells. While the inhibitor of Akt (A6730) or Akt-specific small interference RNA (siRNA) greatly sensitized PC-3 cells to conjugate-induced apoptosis, on the contrary, apoptosis was accelerated by inhibition of ERK (by PD98059 or ERK siRNA) in case of LNCaP cells, both ultimately culminating in the expression of cleaved caspase-3 protein. Moreover, anti-androgenic activity of the conjugate was mediated by decreased expression of AR and its co-activators (SRC-1, GRIP-1), thus interfering in their interactions with AR. All these data suggests that conjugate-induced inhibition of cell proliferation and induction of apoptosis are partly mediated by the down regulation of AR, Akt, and ERK signaling. These observations provide a rationale for devising novel therapeutic approaches for treating PCa by using conjugate alone or in combination with other therapeutics.

Membrane-tethered AKT kinase regulates basal synaptic transmission and early phase LTP expression by modulation of post-synaptic AMPA receptor level

“…Prior to the evaluation of AKT role in eLTP, we assessed the impact of AKT inhibition on basal synaptic activity in acute hippocampal slices using A6730, a potent AKT inhibitor (Hu et al, ; Katengua‐Thamahane et al, ; Nikhil et al, ; Tomas et al, ; You et al, ). A6730 is highly specific to AKT1 and AKT2 isoforms, while having a minimal impact on AKT3 activity (Lindsley et al, ) and a negligible influence on the activity of other enzymes, in contrast to known pan‐AKT inhibitors (Barnett et al, ).…”

KCNN4 Promotes Invasion and Metastasis through the MAPK/ERK Pathway in Hepatocellular Carcinoma

“…The MAPK pathway is active in cell proliferation, differentiation, migration, senescence, and apoptosis 34. There is extensive evidence that the MAPK/ERK pathway plays important roles in various types of cancer, such as prostate cancer, gastric cancer, and renal cell carcinoma 35–37. Some scholars speculate that the MAPK/ERK pathway is associated with resistance to chemotherapeutic agents in human cancers, such as head and neck squamous cell carcinoma and lung cancer, as well as HCC 38.…”

Dietary Polyphenols in Prevention and Treatment of Prostate Cancer

“…PTER-isothiocyanate, a conjugate of PTER inhibits the AR-regulated pathways in PCa cells. The conjugate significantly repressed cell proliferation, induced apoptosis by modulating phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK)/ERK pathways, arrested cell cycles, abrogated DHT induced activation, and down regulated AR expression in LNCaP cells [ 68 ]. PTER treatment inhibited cell proliferation in a dose-dependent manner in p53 wild type LNCaP and p53 null PC3 cells.…”